Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911764100> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2911764100 abstract "BACKGROUND: The addition of antiangiogenic therapies, such as bevacizumab and aflibercept, resulted in overall survival (OS) gain for patients with metastatic colorectal (mCRC). Recently the CORRECT trial demonstrated that regorafenib, an oral multi-kinase inhibitor, also led to improved OS in patients with refractory mCRC. However, the efficacy and safety of regorafenib has not been described in our region, as neither the outcomes following treatment with aflibercept. OBJECTIVE: To evaluate the overall treatment outcomes of Brazilian patients treated with regorafenib as well as according to type of prior antiangiogenic agent, aflibercept (Group A) or bevacizumab (Group B). METHODS: Retrospective unicenter study of mCRC patients treated with regorafenibe within an Expanded Access Program. RESULTS: We included 24 patients: 14 received B and 10, received A. Most patients had colon cancer and all had ECOG 0 or 1. Wild type RAS mCRC was present in 30% of Group A and in 42.8% of Group B. The best response by RECIST 1.1 was stable disease. Median OS times were 8.15 months in Group A, 5.8 months in Group B and 6.16 months for the whole group. Cavitation of pulmonary metastases (45% in Group B and 66%% in Group A) did not influence OS. Nearly 80% of Group A patients received post-progression treatments versus 35.7% in Group B. Fatigue, hand-foot skin reactions, elevated liver enzymes and arterial hypertension were the most common adverse events related to regorafenib, with grade 2/3 occurring in 90% of Group A and in 78.50% of Group B. There were no grade 4 toxicities. CONCLUSION: In this retrospective series, the median OS of patients treated with regorafenib after bevacizumab was similar to that reported by phase III trials. For those previously treated with aflibercept, the median OS was numerically longer in comparison with the bevacizumab group, although this could be explained by selection bias. The toxicity profile of regorafenibe was also similar to that described in the literature except for less diarrhea, which was rare among Brazilian patients." @default.
- W2911764100 created "2019-02-21" @default.
- W2911764100 creator A5005617375 @default.
- W2911764100 creator A5009198553 @default.
- W2911764100 creator A5010940205 @default.
- W2911764100 creator A5027376199 @default.
- W2911764100 creator A5050130816 @default.
- W2911764100 creator A5061506752 @default.
- W2911764100 creator A5072207853 @default.
- W2911764100 creator A5072862368 @default.
- W2911764100 creator A5086819111 @default.
- W2911764100 date "2017-01-01" @default.
- W2911764100 modified "2023-10-18" @default.
- W2911764100 title "Use of regorafenibe in patients with metastastic colorretal cancer previously treated with bevacizumab or aflibercept: uni-institutional clinical experience" @default.
- W2911764100 doi "https://doi.org/10.26790/bjo20171346a177" @default.
- W2911764100 hasPublicationYear "2017" @default.
- W2911764100 type Work @default.
- W2911764100 sameAs 2911764100 @default.
- W2911764100 citedByCount "0" @default.
- W2911764100 crossrefType "journal-article" @default.
- W2911764100 hasAuthorship W2911764100A5005617375 @default.
- W2911764100 hasAuthorship W2911764100A5009198553 @default.
- W2911764100 hasAuthorship W2911764100A5010940205 @default.
- W2911764100 hasAuthorship W2911764100A5027376199 @default.
- W2911764100 hasAuthorship W2911764100A5050130816 @default.
- W2911764100 hasAuthorship W2911764100A5061506752 @default.
- W2911764100 hasAuthorship W2911764100A5072207853 @default.
- W2911764100 hasAuthorship W2911764100A5072862368 @default.
- W2911764100 hasAuthorship W2911764100A5086819111 @default.
- W2911764100 hasBestOaLocation W29117641001 @default.
- W2911764100 hasConcept C121332964 @default.
- W2911764100 hasConcept C121608353 @default.
- W2911764100 hasConcept C126322002 @default.
- W2911764100 hasConcept C141071460 @default.
- W2911764100 hasConcept C142424586 @default.
- W2911764100 hasConcept C143998085 @default.
- W2911764100 hasConcept C197934379 @default.
- W2911764100 hasConcept C2776248978 @default.
- W2911764100 hasConcept C2776694085 @default.
- W2911764100 hasConcept C2777785397 @default.
- W2911764100 hasConcept C2777802072 @default.
- W2911764100 hasConcept C2778749236 @default.
- W2911764100 hasConcept C526805850 @default.
- W2911764100 hasConcept C71924100 @default.
- W2911764100 hasConcept C87355193 @default.
- W2911764100 hasConcept C90924648 @default.
- W2911764100 hasConceptScore W2911764100C121332964 @default.
- W2911764100 hasConceptScore W2911764100C121608353 @default.
- W2911764100 hasConceptScore W2911764100C126322002 @default.
- W2911764100 hasConceptScore W2911764100C141071460 @default.
- W2911764100 hasConceptScore W2911764100C142424586 @default.
- W2911764100 hasConceptScore W2911764100C143998085 @default.
- W2911764100 hasConceptScore W2911764100C197934379 @default.
- W2911764100 hasConceptScore W2911764100C2776248978 @default.
- W2911764100 hasConceptScore W2911764100C2776694085 @default.
- W2911764100 hasConceptScore W2911764100C2777785397 @default.
- W2911764100 hasConceptScore W2911764100C2777802072 @default.
- W2911764100 hasConceptScore W2911764100C2778749236 @default.
- W2911764100 hasConceptScore W2911764100C526805850 @default.
- W2911764100 hasConceptScore W2911764100C71924100 @default.
- W2911764100 hasConceptScore W2911764100C87355193 @default.
- W2911764100 hasConceptScore W2911764100C90924648 @default.
- W2911764100 hasIssue "46" @default.
- W2911764100 hasLocation W29117641001 @default.
- W2911764100 hasOpenAccess W2911764100 @default.
- W2911764100 hasPrimaryLocation W29117641001 @default.
- W2911764100 hasRelatedWork W1965063355 @default.
- W2911764100 hasRelatedWork W2066299572 @default.
- W2911764100 hasRelatedWork W2075960712 @default.
- W2911764100 hasRelatedWork W2339468442 @default.
- W2911764100 hasRelatedWork W3030758306 @default.
- W2911764100 hasRelatedWork W3030909497 @default.
- W2911764100 hasRelatedWork W3142077694 @default.
- W2911764100 hasRelatedWork W362031829 @default.
- W2911764100 hasRelatedWork W368481824 @default.
- W2911764100 hasRelatedWork W861557199 @default.
- W2911764100 hasVolume "13" @default.
- W2911764100 isParatext "false" @default.
- W2911764100 isRetracted "false" @default.
- W2911764100 magId "2911764100" @default.
- W2911764100 workType "article" @default.